Pharmacologic management of neuropathic pain: Evidence-based recommendations

@article{Dworkin2007PharmacologicMO,
  title={Pharmacologic management of neuropathic pain: Evidence-based recommendations},
  author={Robert H. Dworkin and Alec B. O’Connor and Miroslav Backonja and John T Farrar and Mark S Wallace},
  journal={PAIN},
  year={2007},
  volume={132},
  pages={237-251}
}
Abstract Patients with neuropathic pain (NP) are challenging to manage and evidence‐based clinical recommendations for pharmacologic management are needed. Systematic literature reviews, randomized clinical trials, and existing guidelines were evaluated at a consensus meeting. Medications were considered for recommendation if their efficacy was supported by at least one methodologically‐sound, randomized clinical trial (RCT) demonstrating superiority to placebo or a relevant comparison… Expand
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
TLDR
The objectives of the current article are to review the Neuropathic Pain Special Interest Group guidelines for the pharmacological management of neuropathic pain and to provide a brief overview of several recent clinical trials. Expand
Treatment of neuropathic pain: an overview of recent guidelines.
TLDR
Evidence-based guidelines for the pharmacologic management of neuropathic pain that take into account clinical efficacy, adverse effects, impact on health-related quality of life, convenience, and costs are developed. Expand
Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?
TLDR
Improving the current way of conducting clinical trials in NP could contribute to reduce therapeutic failures and may have an impact on future therapeutic algorithms. Expand
The evidence for pharmacological treatment of neuropathic pain
TLDR
Large‐scale drug trials that aim to identify possible subgroups of patients who are likely to respond to specific drugs are needed to test the hypothesis that a mechanism‐based classification may help improve treatment of the individual patients. Expand
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
TLDR
The results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain and allow a strong recommendation for use and proposal as first-line treatment in neuropathicPain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin. Expand
Treatment of neuropathic pain
  • E. Sohn
  • Medicine
  • Journal of the Korean Medical Association
  • 2021
TLDR
It is impossible to completely cure neuropathic pain; however, therapeutic goals must be realistically discussed to improve patient compliance and additional studies based on pathophysiological mechanisms should be conducted to improve the management of Neuropathic pain. Expand
Toward a definition of pharmacoresistant neuropathic pain
TLDR
At present there is devoid of detailed information on mechanisms of spontaneous and stimulus-evoked neuropathic pain which offsets a mechanism based treatment approach with available drugs and strategies on how to identify responders/ non-responders are lacking. Expand
Treatment of Neuropathic Pain
TLDR
Evidence supports first-line trials of anticonvulsants, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors, alone or in certain combinations, and palliative care principles are highly applicable in the treatment of chronic neuropathic pain. Expand
Pharmacological treatment of central neuropathic pain: consensus of the Brazilian Academy of Neurology.
TLDR
The CNP approach must be individualized, taking into account the availability of medication, the profile of adverse effects, including addiction risk, and patients' comorbidities. Expand
Interventional management of neuropathic pain: NeuPSIG recommendations
TLDR
Based on the available data, it is recommended not to use sympathetic blocks for PHN nor radiofrequency lesions for radiculopathy, and four weak recommendations can be made due to the paucity of high‐quality clinical trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 180 REFERENCES
EFNS guidelines on pharmacological treatment of neuropathic pain
TLDR
Evaluated trials provide level A evidence for the efficacy of tricyclic antidepressants, gabapentin, pregabalin and opioids, with a large number of class I trials, followed by topical lidocaine and the newer antidepressants venlafaxine and duloxetine. Expand
Algorithm for neuropathic pain treatment : An evidence based proposal
New studies of the treatment of neuropathic pain have increased the need for an updated review of randomized, double-blind, placebocontrolled trials to support an evidence based algorithm to treatExpand
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
BACKGROUND Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain. Despite its prevalence, neuropathic pain is oftenExpand
Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials.
TLDR
Short-term studies provide only equivocal evidence regarding the efficacy of opioids in reducing the intensity of neuropathic pain, and further RCTs are needed to establish their long-term efficacy, safety, and effects on quality of life. Expand
Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.
TLDR
Randomized controlled clinical trials of gabapentin, the 5% lidocaine patch, opioid analgesics, tramadol hydrochloride, and tricyclic antidepressants provide an evidence-based approach to the treatment of neuropathic pain. Expand
Antidepressants for neuropathic pain.
TLDR
This update has provided additional confirmation on the effectiveness of antidepressants for neuropathic pain and has provided new information on another antidepressant - venlafaxine. Expand
Oral opioid therapy for chronic peripheral and central neuropathic pain.
TLDR
The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses, and higher doses produced more side effects without significant additional benefit in terms of other outcome measures. Expand
Systemic Administration of Local Anesthetics to Relieve Neuropathic Pain: A Systematic Review and Meta-Analysis
TLDR
Lidocaine and mexiletine produced no major adverse events in controlled clinical trials, were superior to placebo to relieve neuropathic pain, and were as effective as other analgesics used for this condition. Expand
Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.
TLDR
Controlled-release oxycodone is an effective analgesic for the management of steady pain, paroxysmal spontaneous pain, and allodynia, which frequently characterize postherpetic neuralgia. Expand
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
TLDR
This study shows that gabapentin reduces pain and improves some quality‐of‐life measures in patients with a wide range of neuropathic pain syndromes. Expand
...
1
2
3
4
5
...